La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
KPC PharmaceuticalsInc Résultats passés
Passé contrôle des critères 4/6
KPC PharmaceuticalsInc's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 0.7% per year. KPC PharmaceuticalsInc's return on equity is 7.9%, and it has net margins of 5.7%.
Informations clés
-0.6%
Taux de croissance des bénéfices
-0.4%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 0.7% |
| Rendement des fonds propres | 7.9% |
| Marge nette | 5.7% |
| Prochaine mise à jour des résultats | 23 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20
Jul 25
Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)
Jun 25We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt
Jun 04KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues
Mar 28Ventilation des recettes et des dépenses
Comment KPC PharmaceuticalsInc gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 7,646 | 432 | 2,705 | 72 |
| 31 Dec 23 | 7,703 | 445 | 2,791 | 71 |
| 30 Sep 23 | 7,700 | 397 | 2,737 | 39 |
| 30 Jun 23 | 7,825 | 390 | 2,815 | 46 |
| 31 Mar 23 | 7,828 | 400 | 2,852 | 57 |
| 31 Dec 22 | 8,282 | 383 | 2,851 | 70 |
| 30 Sep 22 | 8,419 | 446 | 2,865 | 102 |
| 30 Jun 22 | 8,388 | 392 | 2,825 | 108 |
| 31 Mar 22 | 8,722 | 427 | 2,821 | 104 |
| 31 Dec 21 | 8,254 | 508 | 2,815 | 101 |
| 30 Sep 21 | 8,321 | 540 | 2,806 | 140 |
| 30 Jun 21 | 8,386 | 564 | 2,874 | 139 |
| 31 Mar 21 | 8,045 | 560 | 2,834 | 145 |
| 01 Jan 21 | 7,717 | 457 | 2,672 | 128 |
| 30 Sep 20 | 7,779 | 445 | 2,952 | 103 |
| 30 Jun 20 | 7,788 | 444 | 2,990 | 93 |
| 31 Mar 20 | 7,910 | 443 | 3,094 | 79 |
| 31 Dec 19 | 8,120 | 454 | 3,337 | 84 |
| 30 Sep 19 | 7,817 | 429 | 3,226 | 77 |
| 30 Jun 19 | 7,473 | 390 | 3,159 | 83 |
| 31 Mar 19 | 7,237 | 356 | 3,062 | 77 |
| 31 Dec 18 | 7,102 | 336 | 3,000 | 83 |
| 30 Sep 18 | 6,797 | 316 | 2,842 | 70 |
| 30 Jun 18 | 6,507 | 295 | 2,641 | 90 |
| 31 Mar 18 | 6,280 | 318 | 2,379 | 83 |
| 31 Dec 17 | 5,852 | 330 | 2,130 | 63 |
| 30 Sep 17 | 5,637 | 357 | 1,936 | 40 |
| 30 Jun 17 | 5,330 | 374 | 1,746 | 0 |
| 31 Mar 17 | 5,170 | 416 | 1,618 | 0 |
| 31 Dec 16 | 5,101 | 407 | 1,519 | 0 |
| 30 Sep 16 | 5,161 | 440 | 1,295 | 0 |
| 30 Jun 16 | 5,227 | 448 | 1,304 | 0 |
| 31 Mar 16 | 5,049 | 433 | 1,224 | 0 |
| 31 Dec 15 | 4,916 | 421 | 1,177 | 0 |
| 30 Sep 15 | 4,588 | 404 | 1,076 | 0 |
| 30 Jun 15 | 4,456 | 367 | 983 | 0 |
| 31 Mar 15 | 4,361 | 308 | 990 | 0 |
| 31 Dec 14 | 4,316 | 289 | 931 | 0 |
| 30 Sep 14 | 4,038 | 264 | 904 | 0 |
| 30 Jun 14 | 3,860 | 258 | 830 | 0 |
| 31 Mar 14 | 3,668 | 243 | 725 | 0 |
| 31 Dec 13 | 3,584 | 232 | 728 | 0 |
| 30 Sep 13 | 3,337 | 223 | 674 | 0 |
Des revenus de qualité: 600422 has high quality earnings.
Augmentation de la marge bénéficiaire: 600422's current net profit margins (5.7%) are higher than last year (5.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 600422's earnings have declined by 0.6% per year over the past 5 years.
Accélération de la croissance: 600422's earnings growth over the past year (8.2%) exceeds its 5-year average (-0.6% per year).
Bénéfices par rapport au secteur d'activité: 600422 earnings growth over the past year (8.2%) exceeded the Pharmaceuticals industry -0.8%.
Rendement des fonds propres
ROE élevé: 600422's Return on Equity (7.9%) is considered low.